Literature DB >> 23521156

Clusterin associates specifically with Aβ40 in Alzheimer's disease brain tissue.

David R Howlett1, Tibor Hortobágyi, Paul T Francis.   

Abstract

Genome-wide association studies have pointed to clusterin (apolipoprotein J) as being linked to the occurrence of Alzheimer's disease (AD); studies have identified the protein as a possible biomarker. The association between clusterin and senile plaques in AD brain is well known, and clusterin levels in AD brain are 40% higher than that in control subjects. The present study investigates, immunohistochemically, the association between clusterin and Aβ peptides in AD and control cortex. A unique and specific association between clusterin and Aβ40 was observed in plaques in the cerebral cortex from AD subjects in that only plaques that contained Aβ40 showed clusterin immunoreactivity, while the many plaques with Aβ42 alone lacked clusterin labeling. Cerebrovascular Aβ in AD brain generally lacked Aβ42 but was positively labeled by both the Aβ40 and the clusterin antibodies. In control subjects, however, Aβ40 was absent from plaques, although very occasional plaques were found to be labeled by both the Aβ42 and the clusterin antibodies. Overall, in AD, but not aged control brain, clusterin was associated specifically with the Aβ40 form of Aβ in the brain. The lack of clusterin in association with Aβ42 may be a significant feature in neuronal loss and neurodegeneration in the disease state.
© 2013 The Authors; Brain Pathology © 2013 International Society of Neuropathology.

Entities:  

Keywords:  Alzheimer's disease; amyloid beta-protein; apolipoprotein J; biomarker; clusterin

Mesh:

Substances:

Year:  2013        PMID: 23521156      PMCID: PMC8029492          DOI: 10.1111/bpa.12057

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  27 in total

1.  Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.

Authors:  D R Howlett; K Bowler; P E Soden; D Riddell; J B Davis; J C Richardson; S A Burbidge; M I Gonzalez; E A Irving; A Lawman; G Miglio; E L Dawson; E R Howlett; I Hussain
Journal:  Histol Histopathol       Date:  2008-01       Impact factor: 2.303

Review 2.  Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.

Authors:  Simon Lovestone; Andreas Güntert; Abdul Hye; Steven Lynham; Madhav Thambisetty; Malcolm Ward
Journal:  Expert Rev Proteomics       Date:  2007-04       Impact factor: 3.940

3.  Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study.

Authors:  P Giannakopoulos; E Kövari; L E French; I Viard; P R Hof; C Bouras
Journal:  Acta Neuropathol       Date:  1998-04       Impact factor: 17.088

4.  Diffuse type of senile plaques in the brains of Alzheimer-type dementia.

Authors:  H Yamaguchi; S Hirai; M Morimatsu; M Shoji; Y Harigaya
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

5.  Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro.

Authors:  I B Fritz; K Burdzy; B Sétchell; O Blaschuk
Journal:  Biol Reprod       Date:  1983-06       Impact factor: 4.285

6.  Functional and structural properties of lipid-associated apolipoprotein J (clusterin).

Authors:  M Calero; T Tokuda; A Rostagno; A Kumar; B Zlokovic; B Frangione; J Ghiso
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

7.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

9.  Distribution of clusterin in Alzheimer brain tissue.

Authors:  P L McGeer; T Kawamata; D G Walker
Journal:  Brain Res       Date:  1992-05-08       Impact factor: 3.252

10.  Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway.

Authors:  R Killick; E M Ribe; R Al-Shawi; B Malik; C Hooper; C Fernandes; R Dobson; P M Nolan; A Lourdusamy; S Furney; K Lin; G Breen; R Wroe; A W M To; K Leroy; M Causevic; A Usardi; M Robinson; W Noble; R Williamson; K Lunnon; S Kellie; C H Reynolds; C Bazenet; A Hodges; J-P Brion; J Stephenson; J Paul Simons; Simon Lovestone
Journal:  Mol Psychiatry       Date:  2012-11-20       Impact factor: 15.992

View more
  13 in total

1.  Beta-amyloid deposition in chronic traumatic encephalopathy.

Authors:  Thor D Stein; Philip H Montenigro; Victor E Alvarez; Weiming Xia; John F Crary; Yorghos Tripodis; Daniel H Daneshvar; Jesse Mez; Todd Solomon; Gaoyuan Meng; Caroline A Kubilus; Kerry A Cormier; Steven Meng; Katharine Babcock; Patrick Kiernan; Lauren Murphy; Christopher J Nowinski; Brett Martin; Diane Dixon; Robert A Stern; Robert C Cantu; Neil W Kowall; Ann C McKee
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

2.  Clusterin Binding Modulates the Aggregation and Neurotoxicity of Amyloid-β(1-42).

Authors:  Yun-Mi Kim; SuJi Park; Su Yeon Choi; Shin Bi Oh; MinKyo Jung; Chan-Gi Pack; Jung Jin Hwang; Eunyoung Tak; Joo-Yong Lee
Journal:  Mol Neurobiol       Date:  2022-07-29       Impact factor: 5.682

3.  A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Authors:  Yuetiva Deming; Jian Xia; Yefei Cai; Jenny Lord; Peter Holmans; Sarah Bertelsen; David Holtzman; John C Morris; Kelly Bales; Eve H Pickering; John Kauwe; Alison Goate; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2015-09-25       Impact factor: 4.673

4.  Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA.

Authors:  Oskar Karlsson; Anna-Lena Berg; Jörg Hanrieder; Gunnel Arnerup; Anna-Karin Lindström; Eva B Brittebo
Journal:  Arch Toxicol       Date:  2014-05-06       Impact factor: 5.153

5.  Association between clusterin gene polymorphism rs11136000 and late-onset Alzheimer's disease susceptibility: A review and meta-analysis of case-control studies.

Authors:  Wenjin Du; Jiping Tan; Wei Xu; Jinwen Chen; Luning Wang
Journal:  Exp Ther Med       Date:  2016-09-21       Impact factor: 2.447

6.  Clusterin/Apolipoprotein J immunoreactivity is associated with white matter damage in cerebral small vessel diseases.

Authors:  Lucinda Craggs; Julie Taylor; Janet Y Slade; Aiqing Chen; Christian Hagel; Gregor Kuhlenbaeumer; Anne Borjesson-Hanson; Matti Viitanen; Hannu Kalimo; Vincent Deramecourt; Arthur E Oakley; Raj N Kalaria
Journal:  Neuropathol Appl Neurobiol       Date:  2015-06-17       Impact factor: 8.090

7.  Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.

Authors:  J Scott Miners; Polly Clarke; Seth Love
Journal:  Brain Pathol       Date:  2016-07-08       Impact factor: 6.508

Review 8.  Blood-brain-barriers in aging and in Alzheimer's disease.

Authors:  Fernanda Marques; João Carlos Sousa; Nuno Sousa; Joana Almeida Palha
Journal:  Mol Neurodegener       Date:  2013-10-22       Impact factor: 14.195

9.  Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis.

Authors:  Sofía Fernández-de-Retana; Mary Cano-Sarabia; Paula Marazuela; Jose Luis Sánchez-Quesada; Annabel Garcia-Leon; Alex Montañola; Joan Montaner; Daniel Maspoch; Mar Hernández-Guillamon
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

10.  Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy.

Authors:  A Manousopoulou; M Gatherer; C Smith; J A R Nicoll; C H Woelk; M Johnson; R Kalaria; J Attems; S D Garbis; R O Carare
Journal:  Neuropathol Appl Neurobiol       Date:  2016-10-05       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.